Contributions of HIV infection in the hypothalamus and substance abuse/use to HPT dysregulation

Psychoneuroendocrinology

Volumn 36, Issue 5, 2011, Pages 710-719

  Langford, Dianne ^a   Baron, David ^b   Joy, Javed ^c   Del Valle, Luis ^d   Shack, Jonathon ^c  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Friends Hospital   (United States)

^d LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; Hypothalamus; Substance abuse; Thyroid

Indexed keywords

ANTIRETROVIRUS AGENT; OXYTOCIN; THYROTROPIN; VASOPRESSIN;

ADULT; AGING; ARTICLE; AUTOPSY; BRAIN NERVE CELL; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS THYROID SYSTEM; LIFESPAN; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE SYSTEM; NEUROPSYCHIATRY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; HYPOTHALAMUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RETROSPECTIVE STUDIES; SUBSTANCE-RELATED DISORDERS; THYROID GLAND; THYROID HORMONES; YOUNG ADULT;

EID: 79955522064     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2010.10.005     Document Type: Article

References (49)

1. Afhami S., Haghpanah V., Heshmat R., Rasoulinejad M., Izadi M., Lashkari A., Tavangar S.M., Hajiabdolbaghi M., Mohraz M., Larijani B. Assessment of the factors involving in the development of hypothyroidism in HIV-infected patients: a case-control study. Infection 2007, 35:334-338.
2. Alzoubi K.H., Gerges N.Z., Alkadhi K.A. Levothyroxin restores hypothyroidism-induced impairment of LTP of hippocampal CA1: electrophysiological and molecular studies. Exp. Neurol. 2005, 195:330-341.
3. Beltran S., Lescure F.X., Desailloud R., Douadi Y., Smail A., El Esper I., Arlot S., Schmit J.L. Increased prevalence of hypothyroidism among human immunodeficiency virus-infected patients: a need for screening. Clin. Infect. Dis. 2003, 37:579-583.
4. Biondi B., Cooper D.S. The clinical significance of subclinical thyroid dysfunction. Endocr. Rev. 2008, 29:76-131.
5. Bongiovanni M., Adorni F., Casana M., Tordato F., Tincati C., Cicconi P., Bini T., d'Arminio Monforte A. Subclinical hypothyroidism in HIV-infected subjects. J. Antimicrob. Chemother. 2006, 58:1086-1089.
6. Brown L.S., Singer F., Killian P. Endocrine complications of AIDS and drug addiction. Endocrinol. Metab. Clin. North Am. 1991, 20:655-673.
7. Budziszewska B., Jaworska-Feil L., Lason W. The effect of repeated amphetamine and cocaine administration on adrenal, gonadal and thyroid hormone levels in the rat plasma. Exp. Clin. Endocrinol. Diabetes 1996, 104:334-338.
8. Calza L., Manfredi R., Chiodo F. Subclinical hypothyroidism in HIV-infected patients receiving highly active antiretroviral therapy. J. Acquir. Immune. Defic. Syndr. 2002, 31:361-363.
9. CDC: 1981. Pneumocystis Pneumonia-Los Angeles. MMWR Weekly 30, 1-3.
10. Collazos J., Ibarra S., Mayo J. Thyroid hormones in HIV-infected patients in the highly active antiretroviral therapy era: evidence of an interrelation between the thyroid axis and the immune system. AIDS 2003, 17:763-765.
11. Croteau W., Davey J.C., Galton V.A., St Germain D.L. Cloning of the mammalian type II iodothyronine deiodinase. A selenoprotein differentially expressed and regulated in human and rat brain and other tissues. J. Clin. Invest. 1996, 98:405-417.
12. Dawes S., Suarez P., Casey C.Y., Cherner M., Marcotte T.D., Letendre S., Grant I., Heaton R.K. Variable patterns of neuropsychological performance in HIV-1 infection. J. Clin. Exp. Neuropsychol. 2008, 30:613-626.
13. Del Valle L., Pina-Oviedo S. HIV disorders of the brain: pathology and pathogenesis. Front. Biosci. 2006, 11:718-732.
14. Dhopesh V.P., Burke W.M., Maany I., Ravi N.V. Effect of cocaine on thyroid functions. Am. J. Drug Alcohol Abuse 1991, 17:423-427.
15. Everall I.P., Heaton R.K., Marcotte T.D., Ellis R.J., McCutchan J.A., Atkinson J.H., Grant I., Mallory M., Masliah E. Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. Brain Pathol. 1999, 9:209-217.
16. Fliers E., Alkemade A., Wiersinga W.M., Swaab D.F. Hypothalamic thyroid hormone feedback in health and disease. Prog. Brain Res. 2006, 153:189-207.
17. Gereben B., Kollar A., Harney J.W., Larsen P.R. The mRNA structure has potent regulatory effects on type 2 iodothyronine deiodinase expression. Mol. Endocrinol. 2002, 16:1667-1679.
18. Grappin M., Piroth L., Verges B., Sgro C., Mack G., Buisson M., Duong M., Chavanet P., Portier H. Increased prevalence of subclinical hypothyroidism in HIV patients treated with highly active antiretroviral therapy. AIDS 2000, 14:1070-1072.
19. Hoffmann C.J., Brown T.T. Thyroid function abnormalities in HIV-infected patients. Clin. Infect. Dis. 2007, 45:488-494.
20. Hollowell J.G., Staehling N.W., Flanders W.D., Hannon W.H., Gunter E.W., Spencer C.A., Braverman L.E. Serum TSHT(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab. 2002, 87:489-499.
21. Ketsamathi C., Jongjaroenprasert W., Chailurkit L.O., Udomsubpayakul U., Kiertiburanakul S. Prevalence of thyroid dysfunction in Thai HIV-infected patients. Curr. HIV Res. 2006, 4:463-467.
22. Koutkia P., Mylonakis E., Levin R.M. Human immunodeficiency virus infection and the thyroid. Thyroid 2002, 12:577-582.
23. Kumar M., Kumar A.M., Waldrop D., Antoni M.H., Eisdorfer C. HIV-1 infection and its impact on the HPA axis, cytokines, and cognition. Stress 2003, 6:167-172.
24. Lambert M., Zech F., De Nayer P., Jamez J., Vandercam B. Elevation of serum thyroxine-binding globulin (but not of cortisol-binding globulin and sex hormone-binding globulin) associated with the progression of human immunodeficiency virus infection. Am. J. Med. 1990, 89:748-751.
25. Langford D., Adame A., Grigorian A., Grant I., McCutchan J.A., Ellis R.J., Marcotte T.D., Masliah E. Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J. Acquir. Immune Defic. Syndr. 2003, 34:467-474.
26. Langford D., Grigorian A., Hurford R., Adame A., Ellis R.J., Hansen L., Masliah E. Altered P-glycoprotein expression in AIDS patients with HIV encephalitis. J. Neuropathol. Exp. Neurol. 2004, 63:1038-1047.
27. Langford D., Marquie-Beck J., de Almeida S., Lazzaretto D., Letendre S., Grant I., McCutchan J.A., Masliah E., Ellis R.J. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. J. Neurovirol. 2006, 12:100-107.
28. Langford T.D., Letendre S.L., Marcotte T.D., Ellis R.J., McCutchan J.A., Grant I., Mallory M.E., Hansen L.A., Archibald S., Jernigan T., Masliah E. Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS 2002, 16:1019-1029.
29. LoPresti J.S., Fried J.C., Spencer C.A., Nicoloff J.T. Unique alterations of thyroid hormone indices in the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 1989, 110:970-975.
30. Madeddu G., Spanu A., Chessa F., Calia G.M., Lovigu C., Solinas P., Mannazzu M., Falchi A., Mura M.S., Madeddu G. Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study. Clin. Endocrinol. (Oxf) 2006, 64:375-383.
31. Madge S., Smith C.J., Lampe F.C., Thomas M., Johnson M.A., Youle M., Vanderpump M. No association between HIV disease and its treatment and thyroid function. HIV Med. 2007, 8:22-27.
32. Martinez de Arrieta C., Morte B., Coloma A., Bernal J. The human RC3 gene homolog NRGN contains a thyroid hormone-responsive element located in the first intron. Endocrinology 1999, 140:335-343.
33. Masliah E., Heaton R.K., Marcotte T.D., Ellis R.J., Wiley C.A., Mallory M., Achim C.L., McCutchan J.A., Nelson J.A., Atkinson J.H., Grant I. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders HNRC Group. The HIV Neurobehavioral Research Center. Ann. Neurol. 1997, 42:963-972.
34. Moore D.J., Masliah E., Rippeth J.D., Gonzalez R., Carey C.L., Cherner M., Ellis R.J., Achim C.L., Marcotte T.D., Heaton R.K., Grant I. Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS 2006, 20:879-887.
35. Pak J.H., Huang F.L., Li J., Balschun D., Reymann K.G., Chiang C., Westphal H., Huang K.P. Involvement of neurogranin in the modulation of calcium/calmodulin-dependent protein kinase II, synaptic plasticity, and spatial learning: a study with knockout mice. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:11232-11237.
36. Pearce E.N., Farwell A.P., Braverman L.E. Thyroiditis. N. Engl. J. Med. 2003, 348:2646-2655.
37. Price R.W., Brew B.J. The AIDS dementia complex. J. Infect. Dis. 1988, 158:1079-1083.
38. Purba J.S., Hofman M.A., Portegies P., Troost D., Swaab D.F. Decreased number of oxytocin neurons in the paraventricular nucleus of the human hypothalamus in AIDS. Brain 1993, 116 (Pt 4):795-809.
39. Quirino T., Bongiovanni M., Ricci E., Chebat E., Carradori S., Martinelli C., Valsecchi L., Landonio S., Bini T., Bonfanti P. Hypothyroidism in HIV-infected patients who have or have not received HAART. Clin. Infect. Dis. 2004, 38:596-597.
40. Rearden A., Hurford R., Luu N., Kieu E., Sandoval M., Perez-Liz G., Del Valle L., Powell H., Langford T.D. Novel expression of PINCH in the central nervous system and its potential as a biomarker for human immunodeficiency virus-associated neurodegeneration. J. Neurosci. Res. 2008, 86:2535-2542.
41. Salvatore D., Tu H., Harney J.W., Larsen P.R. Type 2 iodothyronine deiodinase is highly expressed in human thyroid. J. Clin. Invest. 1996, 98:962-968.
42. Sellmeyer D.E., Grunfeld C. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr. Rev. 1996, 17:518-532.
43. Sui L., Wang F., Li B.M. Adult-onset hypothyroidism impairs paired-pulse facilitation and long-term potentiation of the rat dorsal hippocampo-medial prefrontal cortex pathway in vivo. Brain Res. 2006, 1096:53-60.
44. Teoh S.K., Mendelson J.H., Woods B.T., Mello N.K., Hallgring E., Anfinsen P., Douglas A., Mercer G. Pituitary volume in men with concurrent heroin and cocaine dependence. J. Clin. Endocrinol. Metab. 1993, 76:1529-1532.
45. Vallat-Decouvelaere A.V., Chretien F., Lorin de la Grandmaison G., Carlier R., Force G., Gray F. The neuropathology of HIV infection in the era of highly active antiretroviral therapy. Ann. Pathol. 2003, 23:408-423.
46. Vescovi P.P., Pezzarossa A. Thyrotropin-releasing hormone-induced GH release after cocaine withdrawal in cocaine addicts. Neuropeptides 1999, 33:522-525.
47. Wiener M., Lo Y., Klein R.S. Abnormal thyroid function in older men with or at risk for HIV infection. HIV Med. 2008, 9:544-549.
48. Wilson L.D., Truong M.P., Barber A.R., Aoki T.T. Anterior pitutiary and pitutiary-dependent target organ function in men infected with the human immunodeficiency virus. Metabolism 1996, 45:738-746.
49. Zirilli L., Orlando G., Diazzi C., Squillace N., Carani C., Guaraldi G., Rochira V. Hypopituitarism and HIV-infection: a new comorbidity in the HAART era?. J. Endocrinol. Invest. 2008, 31:33-38.